Get the Stockscreener App
5.11
6.02%
+0.29
Pre-market:
5.06
-0.05
-0.98%
ImmunityBio Inc stock is currently priced at $5.11, with a 24-hour trading volume of 8.39M.
It has seen a +6.02% increased in the last 24 hours and a -6.07% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.11 pivot point. If it approaches the $5.43 resistance level, significant changes may occur.
Previous Close:
$4.82
Open:
$5.06
24h Volume:
8.39M
Market Cap:
$3.46B
Revenue:
$622.00K
Net Income/Loss:
$-583.20M
P/E Ratio:
-4.4825
EPS:
-1.14
Net Cash Flow:
$-397.34M
1W Performance:
+4.07%
1M Performance:
-6.07%
6M Performance:
+223.42%
1Y Performance:
+117.45%
1D Range:
$4.82
$5.175
52W Range:
$1.25
$6.93
ImmunityBio Inc Stock (IBRX) Company Profile
Name
ImmunityBio Inc
Sector
Industry
Phone
310 883 1300
Address
2040 E MARIPOSA AVENUE, El Segundo
ImmunityBio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
ImmunityBio Inc Stock (IBRX) Latest News
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Benzinga
Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session
Benzinga
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
ImmunityBio Inc Stock (IBRX) Financials Data
ImmunityBio Inc (IBRX) Revenue 2024
IBRX reported a revenue (TTM) of $622.00 thousand for the quarter ending December 31, 2023, a +159.17% rise year-over-year.
ImmunityBio Inc (IBRX) Net Income 2024
IBRX net income (TTM) was -$583.20 million for the quarter ending December 31, 2023, a -40.00% decrease year-over-year.
ImmunityBio Inc (IBRX) Cash Flow 2024
IBRX recorded a free cash flow (TTM) of -$397.34 million for the quarter ending December 31, 2023, a +9.05% increase year-over-year.
ImmunityBio Inc (IBRX) Earnings per Share 2024
IBRX earnings per share (TTM) was -$1.16 for the quarter ending December 31, 2023, a -10.48% decline year-over-year.
ImmunityBio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adcock Richard | CEO & President |
Feb 05 '24 |
Option Exercise |
0.00 |
83,334 |
0 |
286,303 |
| Simon Barry J. | Director |
Jan 31 '24 |
Option Exercise |
0.00 |
57,200 |
0 |
3,145,855 |
| Sachs David C. | Chief Financial Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
70,745 |
0 |
212,673 |
| LAUER REGAN J | Chief Accounting Officer |
Jan 31 '24 |
Option Exercise |
0.00 |
32,872 |
0 |
107,804 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '23 |
Option Exercise |
0.00 |
30,397 |
0 |
152,439 |
| Adcock Richard | CEO & President |
Dec 31 '23 |
Option Exercise |
0.00 |
34,483 |
0 |
220,065 |
| LAUER REGAN J | Chief Accounting Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
21,030 |
0 |
74,932 |
| Sachs David C. | Chief Financial Officer |
Sep 01 '23 |
Option Exercise |
0.00 |
70,744 |
0 |
122,042 |
| LAUER REGAN J | Chief Accounting Officer |
Sep 01 '23 |
Option Exercise |
0.00 |
32,872 |
0 |
53,902 |
| Simon Barry J. | Director |
Sep 01 '23 |
Option Exercise |
0.00 |
57,199 |
0 |
3,088,655 |
About ImmunityBio Inc
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its name to ImmunityBio, Inc. in June 2019. The company was incorporated in 2014 and is based in El Segundo, California. ImmunityBio, Inc. operates as a subsidiary of NantWorks, LLC.
3.08%
9.90%
Cap:
|
Volume (24h):